A Study of 141W94 in Combination With Other Anti-HIV Drugs
To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir, indinavir and nelfinavir after multiple oral dosing. To determine the steady-state pharmacokinetics of saquinavir, indinavir, and nelfinavir in combination with 141W94 after multiple oral dosing. To assess the safety and tolerability of multiple doses of 141W94 when combined with saquinavir, indinavir and nelfinavir.
Drug: Indinavir sulfate
Drug: Nelfinavir mesylate
|Study Design:||Endpoint Classification: Safety Study
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I/II Screening Trial to Identify Potential Partner Compounds to Use in Combination With 141W94|
Patients will be randomized to receive open label 141W94 in combination with saquinavir, indinavir and nelfinavir. The randomized phase will be preceded by a single dose pharmacokinetic interaction study of 141W94 and indinavir in 12 patients. Data from this single dose investigation will be used to determine the dose of indinavir to be used in the randomized phase.
|United States, California|
|Univ of California / San Diego Treatment Ctr|
|San Diego, California, United States, 92103|
|San Francisco, California, United States, 94109|
|United States, North Carolina|
|Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr|
|Durham, North Carolina, United States, 27710|